O-mel-sora: A national multicenter phase II trial of sorafenib in metastatic uveal melanoma.

e20004 Background: Uveal melanoma is the most common primary ocular malignancy in adults, accounting for 70 % of all eye malignancy. Despite adequate local treatment, about 30-50 % of patients develop metastasis and the survival rate is 50% after 10 years and the median survival time is 5-7 months after development of metastasis. There is no consensual and effective treatment in metastatic uveal melanoma. Preclinical data suggest that sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis may be a potential treatment of metastatic uveal melanoma (IC50 values of sorafenib to inhibit cell proliferation was 2.9 µM, similar in both V599EBRaf and WTBRaf melanoma cells). Methods: Multicenter, non-comparative, non-randomized, phase II study was conducted. The primary objective was to determine the non-progression rate at 6 months for patients receiving Sorafenib at dose of 400 mg twice per day orally according the RECIST criteria. Results: 32 patients were enrolled in this study and 29 patient...